“The FDA removes its partial clinical hold of Biodel's (BIOD +3.5%) Phase 2b trial, called Study 3-250, comparing BIOD-531 to Eli Lilly's (LLY -8.1%) Humalog Mix 75/25 in type 2 diabetics who are taking insulin. The agency's action clears the use of the company's investigational U-400 syringes in
“ABSORB III, showed Abbott's (NYSE:ABT) fully dissolving Absorb heart stent was non-inferior (no worse than) to its top-selling XIENCE metallic drug-eluting stent. The results, presented today at the 27th Transcatheter Cardiovascular Therapeutics annual scientific symposium of the Cardiovascular R
“DCR-PH1's mechanism of action is disabling the messenger RNA that encodes glycolate oxidase (GO), the liver enzyme that is involved in the breakdown of hydroxyproline, a component of collagen. Hydroxyproline plays a key role in the buildup of excess oxalate. The production of oxalate is reduced b
“ The stock is at a bargain price for those who missed the first round of appreciation. The stock offers a 100% upside based on the recent high and in fact a higher upside as the company ramps up AUGMENT treatment.”
“This signals that the oncology community recognizes the potential for cancer vaccines to play a major role in immuno-oncology. Cancer vaccines have been largely ignored by investors who at the same time have suspended disbelief for CAR-T companies. This could change. This validation suggests that
“PTC's lead product candidate is Translarna (ataluren) for the treatment of patients with genetic disorders due to a nonsense mutation. It is in clinical development for Duchenne muscular dystrophy (DMD) caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (mnCF)
“Results of the PARADIGM-HF trial showed excellent results for Novartis' novel heart failure medication, which promises to utterly replace ACE inhibitors and angiotensin receptor blockers for certain patients.”
1
Data center REITs slump as VC speech predicts their fade (NYSE:DLR)
FDA places CEL-SCI's late-stage Multikine study in head and neck cancer on full clinical hold; shares down 27% premarket (NYSE:CVM)
IPO Preview: Biohaven Pharmaceuticals (NYSE:BHVN)
Benitec's RNA interference-based hepatitis B candidate reduces HBV DNA by 98.5% in mouse model; shares up 26% (NASDAQ:BNTC)
Sanofi's LixiLan NDA triggers $20M milestone to Zealand Pharma (OTCMKTS:ZLDPF)
SciClone signs on to develop Soligenix's SGX942 in China (NASDAQ:SCLN)
Premarket Biotech Digest: Portola Insider Buying, Pfizer Advances Avelumab, Cara's Positive Data (NASDAQ:PTLA)
FDA lifts partial clinical hold on Biodel's mid-stage study of BIOD-531 (NASDAQ:ALBO)
One-year data show Abbott's Absorb stent on par with XIENCE (NYSE:ABT)
Dicerna's product candidate for PH1 an Orphan Drug in Europe (NYSE:NVO)
OvaScience: Reproducible Results (NASDAQ:OVAS-OLD)
TESARO's (TSRO) CEO Don Miller Discusses on Q1 2015 Results - Earnings Call Transcript
Northwest Bio: FDA Panel Recommendation On Amgen's Cancer Vaccine Is Significant For DCVax-L And DCVax Direct (OTCMKTS:NWBO)
PTC Therapeutics has suitors circling (NASDAQ:PTCT)
Novartis' LCZ696: A New Paradigm For Heart Failure Treatment (NYSE:NVS)